US Stock Futures Fall Ahead Of Consumer-Credit Data

Pre-open movers US stock futures dropped in early pre-market trading, ahead of consumer-credit data. Data on consumer credit for February will be released at 3:00 p.m. ET. Futures for the Dow Jones Industrial Average tumbled 58 points to 16,298.00, while the Standard & Poor's 500 index futures fell 8.40 points to 1,851.70. Futures for the Nasdaq 100 index dropped 29.25 points to 3,508.25. A Peek Into Global Markets European markets were lower today, with the Spanish Ibex Index falling 0.61%, London's FTSE 100 index dropping 0.78% and STOXX Europe 600 Index falling 0.97%. German DAX 30 index tumbled 1.45% and French CAC 40 Index fell 0.66%. German industrial output rose 0.4% on the month in February. Asian markets ended mostly lower today. Japan's Nikkei Stock Average fell 1.69%, Hong Kong's Hang Seng Index declined 0.59% and India's BSE Sensex dropped 0.07% Broker Recommendation Analysts at HSBC upgraded Citigroup C from “underweight” to “neutral.” The target price for Citigroup has been raised from $48 to $51. Citigroup's shares fell 0.17% to $47.03 in pre-market trading. Breaking news

• Republic Airways Holdings RJET today announced that its Board of Directors has authorized Company management to utilize up to $75 million of unrestricted cash to buy back common shares and/or early retire convertible debt during the next 12 months. To read the full news, click here.
• Flamel Technologies FLML today announced that its First-in-Man (FIM) clinical study in healthy volunteers using its proprietary Micropump® technology applied to sodium oxybate has identified formulations that demonstrate the potential to eliminate the second nighttime dose for patients suffering from narcolepsy achieved the objective of one single dose before bedtime for patients suffering from narcolepsy, eliminating the need for a second dose. To read the full news, click here.
• Sun Pharma and Ranbaxy RBXZF today announced entering into definitive agreements for Sun Pharma to acquire 100% of Ranbaxy in an all-stock transaction. To read the full news, click here.
• Mallinckrodt plc MNK, a leading global specialty pharmaceuticals company, and Questcor Pharmaceuticals QCOR, a high-growth biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion. To read the full news, click here.